Our News
CN Bio expands service offering to support oncology drug discovery
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system Represents first implementation of intellectual property licensed from Vanderbilt University to provide human-relevant...
Changing Times, Why Pharmacokinetics Matter in Drug Discovery
Drug discovery should be simple. Deliver the right molecule, antibody, new modality, or cell to the right target within the right organ at the right concentration. Once you have ensured there are no unwanted effects elsewhere in the body, you have developed a safe and...
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect on human health Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ...
Lonza and CN Bio Announce Distribution Agreement
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM...
Of Mice and Men – Will human organ-on-a-chip disease models replace animal use?
The aim of organ-on-a-chip (OOC) technology is to more accurately replicate human physiology in vitro to overcome the relevance limitations of current approaches, and the field is progressing at a rapid pace! Many hundreds of academic researchers are choosing to work...
CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease
Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver cirrhosis Adoption follows successful collaboration demonstrating value of PhysioMimix’s ability to recapitulate...
Cell4Pharma agreement
Today we signed a supply agreement with Dutch Company Cell4Pharma to access their industry-validated conditionally immortalised Renal Proximal Tubule Epithelial Cell (ciPTEC) lines for use with our PhysioMimix OOC Systems. Our PhysioMimix OOC systems, which are...
CN Bio FDA collaboration expanded
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to evaluate CN Bio’s PhysioMimix lung-on-a-chip platform in addition to deepening existing research collaboration for liver studies...
NAFLD vs MAFLD: could a name change impact the progression of liver disease research?
Liver disease is a serious worldwide problem linked to approximately two million deaths per year and in many cases is entirely preventable (Sumeet et al, 2019). One of the most common causes of chronic liver disease is non-alcoholic fatty liver disease (NAFLD), which...
Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro...